Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orchid completes sale of injectables business to Hospira

This article was originally published in Scrip

Executive Summary

Orchid Chemicals and Pharmaceuticals has completed the sale and transfer of its generic injectable finished dosage business to Hospira Inc's Indian subsidiary. The transaction included Orchid’s betalactam injectable antibiotics manufacturing complex and formulations R&D facility at Irungattukottai, Chennai, and its generic injectable product portfolio and pipeline. About 450 Orchid employees are also expected to move to Hospira. Last December, Hospira had Orchid's injectables business for about $400 million, giving it a direct presence in India as also access to cost-effective production facilities for generic injectables, among other gains (scripnews.com, 17 December 2009).

You may also be interested in...



Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic

Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.

India 2019 – R&D Highs, Compliance Woes And Other Lows

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

Glenmark Readies New Diabetes Combo In India

Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.

Topics

Related Companies

UsernamePublicRestriction

Register

SC008265

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel